导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.53% | 2346/4773 |
| 近一周 | -2.69% | 2852/5462 |
| 近一月 | -5.32% | 3166/5421 |
| 近一季 | -7.31% | 2357/5209 |
| 近半年 | 0.47% | 1154/4920 |
| 近一年 | 3.16% | 1981/4366 |
| 近两年 | 49.49% | 1479/2954 |
| 近三年 | 33.72% | 908/2253 |
| 成立以来 | 209.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.38% 3609/4961 |
16.06% 1603/5312 |
- - |
- - |
| 2025 | 23.10% 1907/4813 |
0.45% 1847/3635 |
2.92% 1266/4076 |
19.03% 2200/4524 |
0.03% 2278/4813 |
| 2024 | 15.14% 962/3463 |
2.47% 774/2808 |
-0.33% 737/3014 |
15.47% 1709/3129 |
-2.37% 2061/3463 |
| 2023 | -13.44% 1542/2656 |
2.77% 1300/2280 |
-5.68% 1518/2385 |
-5.61% 1344/2515 |
-5.39% 1341/2655 |
| 2022 | -19.91% 916/2207 |
-16.02% 1094/1919 |
9.32% 287/2016 |
-13.17% 851/2113 |
0.47% 1491/2208 |
| 2021 | 1.56% 665/1822 |
-5.24% 912/1255 |
11.10% 401/1330 |
-4.34% 701/1466 |
0.83% 1055/1822 |
| 2020 | 47.64% 195/1250 |
-6.16% 462/1028 |
17.78% 361/1067 |
16.01% 178/1164 |
15.16% 230/1184 |
| 2019 | 39.60% 278/1092 |
25.62% 451/754 |
2.12% 98/804 |
2.21% 315/850 |
6.47% 605/918 |
| 2018 | -21.36% 211/834 |
- - |
- - |
- - |
-12.55% 457/691 |
| 2017 | 30.73% 56/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.02% 138/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.24% 170/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安沪深300增强A VS. 长安沪深300非周期A(740101) |